Skip to main content
. 2022 May 7;3(6):100336. doi: 10.1016/j.jtocrr.2022.100336

Figure 1.

Figure 1

Proportion of patients who received biomarker testing by year of advanced/metastatic diagnosis. Follow-up data are limited in 2021 and data should be interpreted with caution. NGS, next-generation sequencing.